Full Text View
Tabular View
No Study Results Posted
Related Studies
Intramuscular Injections of Risperidone 4-Week Long-Acting Injectable (LAI) Formulation in the Buttock of Subjects With Schizophrenia
This study is ongoing, but not recruiting participants.
Study NCT00821600.   Last updated on March 26, 2009.
Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
Risperidone, Psychotic Disorders
Additional conditions recognized in this trial
Psychotic Disorders
More general conditions related to this trial
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
risperidone 4-week LAI formulation
Additional drug interventions recognized in this trial
Risperidone
More general drug interventions related to this trial
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.


U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services